- Home
- SVRA vs CTMX Comparison
SVRA vs CTMX Comparison
Compare SVRA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- CTMX
- Stock Information
- Founded
- SVRA 2007
- CTMX 2008
- Country
- SVRA United States
- CTMX United States
- Employees
- SVRA N/A
- CTMX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- CTMX Health Care
- Exchange
- SVRA Nasdaq
- CTMX Nasdaq
- Market Cap
- SVRA 527.2M
- CTMX 544.2M
- IPO Year
- SVRA N/A
- CTMX 2015
- Fundamental
- Price
- SVRA $3.41
- CTMX $3.32
- Analyst Decision
- SVRA Buy
- CTMX Strong Buy
- Analyst Count
- SVRA 8
- CTMX 5
- Target Price
- SVRA $6.63
- CTMX $5.30
- AVG Volume (30 Days)
- SVRA 1.1M
- CTMX 4.3M
- Earning Date
- SVRA 11-11-2025
- CTMX 11-06-2025
- Dividend Yield
- SVRA N/A
- CTMX N/A
- EPS Growth
- SVRA N/A
- CTMX 263.20
- EPS
- SVRA N/A
- CTMX 0.49
- Revenue
- SVRA N/A
- CTMX $141,100,000.00
- Revenue This Year
- SVRA N/A
- CTMX N/A
- Revenue Next Year
- SVRA N/A
- CTMX N/A
- P/E Ratio
- SVRA N/A
- CTMX $6.80
- Revenue Growth
- SVRA N/A
- CTMX 18.01
- 52 Week Low
- SVRA $1.89
- CTMX $0.40
- 52 Week High
- SVRA $4.30
- CTMX $3.49
- Technical
- Relative Strength Index (RSI)
- SVRA 52.33
- CTMX 75.86
- Support Level
- SVRA $3.42
- CTMX $3.11
- Resistance Level
- SVRA $3.65
- CTMX $3.39
- Average True Range (ATR)
- SVRA 0.12
- CTMX 0.24
- MACD
- SVRA -0.04
- CTMX 0.10
- Stochastic Oscillator
- SVRA 12.90
- CTMX 90.91
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.